Avecho Biotechnology Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Avecho Biotechnology.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	54.6%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Avecho Biotechnology yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

ASX:AVE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	0	-3	-3	-3	N/A
3/31/2024	0	-3	-3	-3	N/A
12/31/2023	0	-3	-3	-3	N/A
9/30/2023	1	-4	-3	-3	N/A
6/30/2023	1	-4	-2	-2	N/A
3/31/2023	1	-3	-2	-2	N/A
12/31/2022	1	-2	-2	-2	N/A
9/30/2022	1	-2	-2	-2	N/A
6/30/2022	1	-2	-2	-1	N/A
3/31/2022	1	-3	-2	-2	N/A
12/31/2021	1	-3	-3	-3	N/A
9/30/2021	1	-3	-3	-3	N/A
6/30/2021	0	-3	-2	-2	N/A
3/31/2021	0	-3	-2	-2	N/A
12/31/2020	0	-3	-1	-1	N/A
9/30/2020	0	-2	-2	-2	N/A
6/30/2020	0	-2	-2	-2	N/A
3/31/2020	2	-1	-1	-1	N/A
12/31/2019	4	1	1	1	N/A
9/30/2019	4	1	1	1	N/A
6/30/2019	5	0	1	1	N/A
3/31/2019	3	-2	0	0	N/A
12/31/2018	1	-4	-2	-2	N/A
6/30/2018	1	-6	-5	-5	N/A
3/31/2018	1	-7	N/A	-6	N/A
12/31/2017	1	-9	N/A	-6	N/A
6/30/2017	1	-16	N/A	-6	N/A
3/31/2017	1	-17	N/A	-6	N/A
12/31/2016	2	-17	N/A	-6	N/A
9/30/2016	2	-17	N/A	-6	N/A
6/30/2016	3	-17	N/A	-6	N/A
3/31/2016	2	-18	N/A	-7	N/A
12/31/2015	2	-20	N/A	-9	N/A
9/30/2015	2	-17	N/A	-10	N/A
6/30/2015	3	-14	N/A	-11	N/A
3/31/2015	2	-10	N/A	-9	N/A
12/31/2014	2	-7	N/A	-7	N/A
6/30/2014	1	-7	N/A	-7	N/A
3/31/2014	1	-9	N/A	-8	N/A
12/31/2013	1	-11	N/A	-9	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if AVE's forecast earnings growth is above the savings rate (2.4%).

Kazançlar ve Piyasa: Insufficient data to determine if AVE's earnings are forecast to grow faster than the Australian market

Yüksek Büyüme Kazançları: Insufficient data to determine if AVE's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if AVE's revenue is forecast to grow faster than the Australian market.

Yüksek Büyüme Geliri: Insufficient data to determine if AVE's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if AVE's Return on Equity is forecast to be high in 3 years time

Avecho Biotechnology Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

First half 2024 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2023)

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in FY 2021)

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Athenex Submits Avecho's Phytonadione to FDA Pre-IND

Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia

Less than half of directors are independent

Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk

First half 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2021)

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Less than half of directors are independent

Avecho Biotechnology Limited Announces Positive Results for Its Phase IIa Study

Avecho Biotechnology Limited Announces Dosing Commencement for CBD Topical Osteoarthritis Study in collaboration with the Lambert Initiative

Full year 2021 earnings: Revenues miss analyst expectations

Avecho Biotechnology Limited Releases Results for Its Australian Phase I PK Study Characterizing the Absorption Profile of Cannabidiol from Avecho's Proprietary CBD Soft-Gel Product

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD Absorption

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Non-Independent Non-Executive Director David Segal has left the company

Avecho Biotechnology Limited Completes Pharmaceutical CBD Soft-Gel Product

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

Avecho Biotechnology Begins Human Trial on CBD Product

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Avecho Biotechnology Limited Provides TPM Cannabinoid Development Program Update

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin